Pelacarsen phase 2 (AKCEA-APO(a)-LRx)

286 patients with established cardiovascular disease and Lp(a) of 60 mg/dL (150 nmol/L) or more received the hepatocyte-directed antisense oligonucleotide for 6 to 12 months: mean reductions of 35 percent (20 mg every 4 weeks) to 80 percent (20 mg weekly) versus 6 percent on placebo, injection-site reactions the main adverse event. Selected the 80 mg monthly regimen for Lp(a)HORIZON.